Tioga Pharmaceuticals, Inc.

Stuart J.M. Collinson, Ph.D.
Chairman and Chief Executive Officer

Dr. Collinson is a partner at Forward Ventures. Previously he was Chairman, Chief Executive Officer and President of Aurora Biosciences Corporation (acquired by Vertex Pharmaceuticals Inc). Before Aurora, Dr. Collinson held senior management positions at GlaxoWellcome, including Vice President of Gastrointestinal Diseases, and at Baxter International Inc.

Dr. Collinson is a director of Vertex Pharmaceuticals Inc. and several private companies.

Dr. Collinson was awarded an MBA from Harvard Business School and a Ph.D. in Physical Chemistry from the University of Oxford.

collinson@tiogapharma.com

David Urso
Chief Operating Officer and General Counsel

Prior to joining Tioga, Mr. Urso was a Principal at Forward Ventures. He has a scientific background in molecular immunology and is an attorney with experience in corporate securities and corporate partnering transactions in the life science industry.

Before joining Forward Ventures, Mr. Urso was Director of Corporate Development and Legal Affairs at DNA Sciences, Inc. Mr. Urso worked as an attorney in the corporate securities and technology transfer groups at Wilson Sonsini Goodrich & Rosati LLP and at Cooley Godward LLP; and as a bench scientist at SmithKline Beecham and the University of Pennsylvania Medical School.

Mr. Urso received a J.D. from Harvard Law School and a B.A. in Molecular Biology and Philosophy from Reed College.

urso@tiogapharma.com

Allen Mangel, M.D., Ph.D.
Chief Medical Officer

Dr. Allen Mangel is a gastroenterologist and vice president of RTI Health Solutions. Following completion of his medical training, Dr. Mangel did his internship and residency in internal medicine at Duke University Medical Center and then completed his gastroenterology fellowship also at Duke. Following completion of his formal training, he remained on the faculty in the Department of Medicine, Division of Gastroenterology, at Duke for three years. Dr. Mangel also has a Ph.D. from the University of Illinois, where his research focused on control of electrical and mechanical activity in gastrointestinal smooth muscle.

Dr. Mangel has extensive pharmaceutical industry experience, including time at GlaxoSmithKline and Merck & Co. As the Head of Gastroenterology Clinical Development at GlaxoSmithKline, Dr. Mangel led the clinical development of drugs targeting gastrointestinal diseases, most notably irritable bowel syndrome. He has over 80 publications.

Carolyn R. Sikes, Ph.D.
Vice President of Clinical and Scientific Affairs

Dr. Sikes joined Tioga in 2010, bringing 20 years of experience in global medical affairs and drug development, including the approval and commercialization of several medically important medications.  Prior to joining Tioga, Dr. Sikes held various leadership positions at a large global pharmaceutical organization, and has worked in multiple therapeutic areas.  Dr. Sikes has a Ph.D. in Psychobiology/Neuroscience from Duke University and completed a post-doctoral fellowship in Psychoneuroendocrinology at Cornell University Medical Center.

sikes@tiogapharma.com